Compare · HNGR vs ILMN
HNGR vs ILMN
Side-by-side comparison of Hanger Inc. (HNGR) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HNGR and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $29.37B, about 43.0x HNGR ($682.4M).
- ILMN has hit the wire 3 times in the past 4 weeks while HNGR has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 1 for HNGR).
- Company
- Hanger Inc.
- Illumina Inc.
- Price
- $18.73+0.03%
- $194.06-1.49%
- Market cap
- $682.4M
- $29.37B
- 1M return
- -
- +10.86%
- 1Y return
- -
- +76.55%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- 2000
- News (4w)
- 0
- 3
- Recent ratings
- 1
- 25
Hanger Inc.
Hanger, Inc. provides orthotic and prosthetic (O&P) services; and distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings in the United States. It operates through two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and provides payor network contracting services to other O&P providers. The Products & Services segment distributes O&P parts, componentry, and devices to independent O&P providers; and develops specialized rehabilitation technologies and provides evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2020, the company operated approximately 704 patient care clinics, and 112 satellite locations in 46 states and the District of Columbia. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest HNGR
- SEC Form SC 13G/A filed by Hanger Inc. (Amendment)
- SEC Form 15-12G filed by Hanger Inc.
- SEC Form EFFECT filed by Hanger Inc.
- SEC Form 4: Sullivan Kathryn M returned $1,162,988 worth of shares to the company (62,026 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Jones Mark M returned $386,138 worth of shares to the company (20,594 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Pettingill Richard returned $1,465,031 worth of shares to the company (78,135 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Ahmad Asif returned $1,328,194 worth of shares to the company (70,837 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Lucchese Cynthia L returned $1,272,206 worth of shares to the company (67,851 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Begley Christopher B returned $1,432,762 worth of shares to the company (76,414 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Hare Stephen E returned $2,006,419 worth of shares to the company (107,009 units at $18.75), closing all direct ownership in the company
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits